نتایج جستجو برای: taxotere
تعداد نتایج: 880 فیلتر نتایج به سال:
Cisplatin-based chemotherapy regimens of the 1980s have shown a small but significant impact on survival for patients with advanced non-small cell lung cancer (NSCLC). New agents, including docetaxel, have shown encouraging single-agent activity in this disease. This potent microtubule stabilizing agent was selected for clinical development based on its preclinical superiority to paclitaxel. Th...
BACKGROUND Eccrine porocarcinoma is an uncommon neoplasm of the intra-epidermal sweat gland duct. PATIENTS AND METHODS A case of eccrine porocarcinoma in a female renal transplant patient aged 45 years is described with a review of pertinent literature. RESULTS The primary tumour was highly pleomorphic. In places large and small cells merged and focally the former component infiltrated the ...
Docetaxel activity has been documented in many solid tumors, including metastatic breast cancer and non-small cell lung cancer. However, as clinical studies in other tumor types are now being conducted, the validation of an optimal sampling strategy would allow the performance of pharmacokinetics/pharmacodynamics studies with minimum inconvenience for the patient. Six optimal sampling strategie...
Docetaxel (DTX) has excellent efficiency against a wide spectrum of cancers. However, the current clinical formulation has limited its usage, as it causes some severe side effects. Various polymeric nanoparticles have thus been developed as alternative formulations of DTX, but they have been mostly fabricated on a laboratory scale. Previously, we synthesized a novel copolymer, poly(lactide)-D-α...
Docetaxel (Taxotere(®)) is an agent that is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer. In recent years, docetaxel-related interstitial lung disease (ILD) has been reported in several case series studies. The onset of ILD occurred ~10-20 days (median time: 18 days) after docetaxel administration. Here, we reported the case of a patient...
Anticancer drugs have been explored by means of random screening and demonstrated to be active against not only hematologic malignancies but also some solid tumors. Recent progress in the field of molecular biology has identified many new molecular targets for anticancer drugs. In this review, for example, signal-transduction pathways, which are influenced by newer agents like the taxanes (pacl...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید